The 340B program is under attack from CMS and drug manufacturers. Tom Kraus and Jillanne Schulte-Wall help you understand recent threats to the program and how ASHP is fighting back.
Tom Kraus is Vice President for Government Relations at ASHP. He is a graduate of University of Michigan (BS Biology), Georgetown University Law Center (Doctor Of Law), and The Johns Hopkins University (MHS, Health Policy).
Tom previously served as the Chief of Staff and Associate Commissioner for Legislation at the U.S. Food and Drug Administration. He was also a senior policy advisor to Sen. Ted Kennedy and Sen. Tom Harkin on the Senate Health, Education, Labor and Pensions Committee, where he served as Deputy Staff Director for Health.
Jillanne Schulte Wall is the Senior Director of Health & Regulatory Policy for the American Society of Health-System Pharmacists (ASHP) in Bethesda, MD. She serves as ASHP’s primary liaison to federal regulatory agencies and, in conjunction with other members of the Government Relations team, develops and communicates of ASHP’s positions on federal and state laws, regulations, and guidance related to the profession of pharmacy. Additionally, Jillanne works closely with stakeholders in pharmacy, medicine, manufacturing, and patient advocacy on legislative and regulatory issues of importance to ASHP members. Prior to joining ASHP, Jillanne was the Director of Regulatory Affairs for the American Pharmacists Association in Washington, D.C. She began her career as a healthcare attorney at Feldesman Tucker Leifer Fidell LLP in Washington, DC, where she advised healthcare clients on corporate, regulatory, and transactional issues, with a particular emphasis on optimizing performance after the implementation of the Affordable Care Act.